VAL-083: An Important Biological Approach to Fighting Drug-Resistant Tumors
Demonstrating Potency in Clinical Trials
VAL-083 has been evaluated in more than 40 Phase 1 and Phase 2 clinical trials by the U.S. National Cancer Institute and was found to have anti-cancer activities against various cancers, including brain tumors and ovarian cancers.
Glioblastoma Multiforme (GBM) is the most common and lethal form of brain cancer. As a unique small molecule therapeutic, VAL-083 can potentially offer a new paradigm in the treatment of GBM.
Our research supports VAL-083's potential as a new therapeutic option for platinum-resistant ovarian cancer patients whose treatment is underserved by currently available therapy.
Pediatric Brain Tumors
Children with high grade glioma have very limited treatment options. VAL-083 has demonstrated promising activities in the treatment of pediatric brain tumors in NCI clinical trials and our recent preclinical studies, supporting future clinical evaluation.
Our Platform Strategy: Unleashing the Potential of Biology
Our drug development strategy is built on a robust understanding of cancer biology. We use modern scientific approaches to determine where we can solve problems for specific tumor types.
Our team is identifying opportunities where a modernized understanding of the anti-cancer mechanism of VAL-083 suggests that this agent can address an unmet need. By showing that VAL-083 is active where others fail, we can demonstrate that our therapies may have the ability to improve patient survival and quality of life.
Explore Our Scientific Publications & Presentations
Dive deeper into our work by reviewing our robust catalog of scientific publications and presentations.